Inhibition of fibroproliferation by pentoxifylline: Activity of metabolite-1 and lack of role of adenosine receptors

Biochemical Pharmacology

Volumn 52, Issue 4, 1996, Pages 597-602

  Peterson, Theresa C ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

8 phenyltheophylline; Adenosine receptor; Fibroproliferation; Metabolite 1; Methylxanthines; Pentoxifylline

Indexed keywords

8 PHENYLTHEOPHYLLINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; LISOFYLLINE; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR;

ARTICLE; CELL PROLIFERATION; FIBROBLAST; FIBROSIS; IN VITRO STUDY; PRIORITY JOURNAL;

DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HUMANS; PENTOXIFYLLINE; SKIN; THYMIDINE;

EID: 0029957888     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00311-5     Document Type: Article

References (31)

1. Friedman SL, The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 24: 1828-1835, 1993.
2. Peterson TC, Isbrucker RA and Hooper ML, In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacology 28: 259-270, 1994.
3. Slysz GW and Peterson TC, Pentoxifylline and trapidil do not inhibit PDGF binding to PDGF receptors of human and rat fibroblasts. J Leukoc Biol (Suppl) LB68, 1994.
4. Dalziel HH and Westfall DP, Receptors for adenine nucleotides and nucleosides: Subclassification, distribution, and molecular characterization. Pharmacol Rev 46: 449-466, 1994.
5. Fredholm BB and Lindström K, The xanthine derivative 1-(5′-oxohexyl)-3-methyl-7-propyl xanthine (HWA 285) enhances the actions of adenosine. Acta Pharmacol Toxicol 58: 187-192, 1986.
6. Bruns RF, Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem Pharmacol 30: 325-333, 1981.
7. 2B-receptor-mediated cyclic AMP accumulation in primary rat astrocytes. Br J Pharmacol 111: 191-198, 1994.
8. 3H]N-ethylcarboxamidoadenosine (NECA) binding allows the visualization of putative non-A1 adenosine receptors. Brain Res 368: 394-398, 1986.
9. Seale TW, Abla KA, Shamin MT, Carney JM and Daley JW, 3,7-Dimethyl-l-propargylxanthine: A potent and selective in vivo antagonist of adenosine analogs. Life Sci 43: 1671-1684, 1988.
10. Dohlman JG, Payan DG and Goetzl EJ, Generation of a unique fibroblast activating factor by human monocytes. Immunology 52: 577-584, 1984.
11. Denizat F and Lang R, Rapid colorimetric assay for cell growth and survival. J Immunol Methods 89: 271-277, 1986.
12. Zar JH, Biostatistical Methods. Prentice-Hall, Englewood Cliffs, NJ, 1974.
13. Fujimoto K, Yoshida S, Moriyama Y and Sakaguchi T, Absorption, distribution, excretion and metabolism of 1-(5-oxohexyl)theobromine (BL191) in rats. Chem Pharm Bull (Tokyo) 24: 1137-1145, 1976.
14. 14C after oral administration to rats, dogs and humans. Arzneimittel forschung 22: 1933-1937, 1972.
15. Hinze H, Zur pharmakokinetik von 3,7-dimethyl-l-(5-oxo-hexyl)-zanthin (BL191) am menschen. Arzneimittel forschung 22: 1492-1495, 1972.
16. Wills RJ, Waller ES, Puri SK, Ho I and Yakatan G, Influence of food on the bioavailability of Trental (pentoxifylline) in man. Drug Dev Ind Pharm, 7: 385-396, 1981.
17. Luke DR, Rocci M and Hoholick C, Inhibition of pentoxifylline clearance by cimeditine. J Pharm Sci 75: 155-157, 1986.
18. Smith RV, Waller ES, Doluisio JT, Bauza MT, Puri SK, Ho I and Lassman HB, Pharmacokinetics of orally administered pentoxifylline in humans. J Pharm Sci 75: 47-52, 1986.
19. Aviado DM and Dettelbach HR, Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology 35: 407-417, 1984.
20. Ward A and Clissold SP, Pentoxifylline, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 34: 50-97, 1987.
21. Thompson J, Bianco J, Benyunes M, Neubauer M, Slattery J and Fefer A, Phase IB trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res 54: 3436-3441, 1994.
22. Mauro VF, Mauro LS and Hageman JH, Comparison of pentoxifylline pharmacokinetics between smokers and nonsmokers. J Clin Pharmacol 32: 1054-1058, 1992.
23. Reims A, Poirier J, Lecoz F, Midavaine M, Lecocq B, Grange J, Poupon R, Cheymol G and Jaillon P, Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther 47: 354-359, 1990.
24. Cleary JD, Ciprofloxacin and pentoxifylline; a clinically significant drug interaction. Pharmacotherapy 12: 259, 1992.
25. Fuhr U, Anders E-H, Mahr G, Sörgel F and Staib AH, Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 36: 942-948, 1992.
26. Kalow W and Tang B-K, Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49: 44-48, 1991.
27. PA (P450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86: 7696-7700, 1989.
28. Robson RA, Miners JO, Matthews AP, Stupans I, Meller D, McManus ME and Birkett DJ, Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. Biochem Pharmacol 37: 1651-1659, 1988.
29. George J, Murray M, Byth K and Farrell G, Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21: 120-128, 1995.
30. 2 receptors on rat Kupffer cells. Hepatology 19: 1445-1452, 1994.
31. Meskini N, Nemoz G, Okyayuz-Baklouti I, Lagarde M and Prigent A, Phosphodiesterase inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem Pharmacol 47: 781-788, 1994.